PEA Powder Composition With Self-Emulsifying Enteric Bioaccessibility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The low bioavailability of palmitoylethanolamide (PEA) due to its poor enteric bioaccessibility and water solubility limits its effectiveness in medical therapy, despite its pharmacological properties for treating inflammation and pain.
Innovation Solution
A self-emulsifying lipid matrix composition in powder form, comprising PEA, medium chain triglycerides, mono and diglycerides of fatty acids, and hydrophilic surfactants, which forms a liquid emulsion in gastro-enteric fluids, enhancing bioaccessibility by creating mixed micelles with bile salts for absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PEA is administered in conventional forms, then the formulation is simple, but the enteric bioaccessibility is poor
Solution Approach 1:
The patent employs a composite formulation consisting of PEA encapsulated within a lipid matrix (containing medium-chain triglycerides and long-chain triglycerides) combined with hydrophilic surfactants. This composite structure addresses the poor enteric bioaccessibility of PEA by creating a dual-phase system that facilitates both gastric resistance and intestinal emulsification, thereby resolving the contradiction between maintaining simple formulation and achieving reliable bioaccessibility.
Solution Approach 2:
The invention modifies the physical and chemical parameters of PEA delivery by changing its state from pure crystalline powder to an encapsulated form within a lipid-surfactant matrix. This parameter change includes altering the particle size distribution, lipid composition ratios, and surfactant concentrations to optimize emulsification and absorption, thus improving enteric bioaccessibility without excessively complicating the formulation process.
2Reliability
If PEA is micronized to increase surface area, then the contact surface with absorbent epithelium increases, but the water solubility remains poor
Solution Approach 1:
The patent introduces hydrophilic surfactants as intermediary substances that mediate between the lipophilic PEA molecule and the aqueous gastrointestinal environment. These surfactants form mixed micelles with the lipid matrix, creating an intermediate structure that enhances water solubility and facilitates absorption without requiring complex micronization processes. The surfactants act as bridges that resolve the contradiction between poor water solubility and the need for effective absorption.
3Reliability
If a self-emulsifying lipid matrix is used, then the bioaccessibility increases to 50-70%, but the formulation complexity increases
Solution Approach 1:
The patent employs a self-emulsifying lipid matrix that automatically forms emulsions in the gastrointestinal tract without requiring external emulsification devices or complex delivery systems. The formulation contains lipids and surfactants in specific ratios that enable spontaneous emulsification upon contact with gastrointestinal fluids, achieving high bioaccessibility (50-70%) through self-service mechanisms. This approach resolves the contradiction by achieving high performance through intelligent formulation design rather than complex delivery infrastructure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly increases PEA bioaccessibility to 50-70%, improving its absorption and efficacy in treating inflammatory and neuropathic pain conditions.
Implementation Method 1
A self-emulsifying lipid matrix composition in powder form, comprising PEA, medium chain triglycerides, mono and diglycerides of fatty acids, and hydrophilic surfactants, which forms a liquid emulsion in gastro-enteric fluids
Implementation Method 2
enhancing bioaccessibility by creating mixed micelles with bile salts for absorption
Data Source
Figure 1~2(B)
Figure 3~4A
Figure 4B~5A
AI summary
The present invention relates to a solid composition in powder form comprising palmitoylethanolamide (PEA) as an active ingredient, the solid composition being characterized in that it comprises a) a lipid-surfactant phase including the PEA and containing at least one medium chain triglyceride (MTC); at least one mono- and diglyceride of fatty acids; at least one mono- or poly-unsaturated fatty acid, or precursors thereof; at least one hydrophilic surfactant; and b) a hydrophilic phase in the form of granules containing glucose polymers and/or polyols, on which the lipid-surfactant phase is adsorbed. A further object of the present invention is the process for preparing the aforesaid solid composition, in powder form.